| GC34215-5mg |
|
180288-69-1 |
Trastuzumab (Anti-Human HER2, Humanized Antibody)
|
0 |
C6470H10012N1726O2013S42 |
|
|
|
| GC34215-1mg |
|
180288-69-1 |
Trastuzumab (Anti-Human HER2, Humanized Antibody)
|
0 |
C6470H10012N1726O2013S42 |
|
|
|
| GC34214-5mg |
|
331731-18-1 |
Adalimumab (Anti-Human TNF-alpha, Human Antibody)
|
0 |
— |
|
|
|
| GC34214-1mg |
|
331731-18-1 |
Adalimumab (Anti-Human TNF-alpha, Human Antibody)
|
0 |
— |
|
|
|
| GC34213-5mg |
|
815610-63-0 |
Ustekinumab (Anti-Human IL-12/IL-23, Human Antibody)
|
0 |
— |
|
|
|
| GC34213-1mg |
|
815610-63-0 |
Ustekinumab (Anti-Human IL-12/IL-23, Human Antibody)
|
0 |
— |
|
|
|
| GC34212-5mg |
|
— |
|
0 |
— |
|
|
|
| GC34212-1mg |
|
— |
|
0 |
— |
|
|
|
| GC34211-5mg |
|
943609-66-3 |
Vedolizumab (Anti-Human lymphocyte α4β7 integrin, Humanized Antibody)
|
0 |
— |
|
|
|
| GC34211-50mg |
|
943609-66-3 |
Vedolizumab (Anti-Human lymphocyte α4β7 integrin, Humanized Antibody)
|
0 |
— |
|
|
|
| GC34211-25mg |
|
943609-66-3 |
Vedolizumab (Anti-Human lymphocyte α4β7 integrin, Humanized Antibody)
|
0 |
— |
|
|
|
| GC34211-1mg |
|
943609-66-3 |
Vedolizumab (Anti-Human lymphocyte α4β7 integrin, Humanized Antibody)
|
0 |
— |
|
|
|
| GC34210-5mg |
|
— |
Pertuzumab (Anti-Human HER2, Humanized Antibody)
|
0 |
— |
|
|
|
| GC34210-1mg |
|
— |
Pertuzumab (Anti-Human HER2, Humanized Antibody)
|
0 |
— |
|
|
|
| GC34209-25mg |
|
174722-31-7 |
Rituximab (Anti-Human CD20 type I, Chimeric Antibody)
|
0 |
C6416H9874N1688O1987S44 |
|
|
|
| GC34209-5mg |
|
174722-31-7 |
Rituximab (Anti-Human CD20 type I, Chimeric Antibody)
|
0 |
C6416H9874N1688O1987S44 |
|
|
|
| GC34209-1mg |
|
174722-31-7 |
Rituximab (Anti-Human CD20 type I, Chimeric Antibody)
|
0 |
C6416H9874N1688O1987S44 |
|
|
|
| GC34208-25mg |
|
— |
|
0 |
C25H27ClN8 |
|
|
|
| GC34208-10mg |
|
— |
|
0 |
C25H27ClN8 |
|
|
|
| GC34208-5mg |
|
— |
|
0 |
C25H27ClN8 |
|
|
|
